Angela Llobet Martinez

Secukinumab in Moderate-to-Severe Hidradenitis Suppurativa: Primary Endpoint Analysis from the SUNSHINE and SUNRISE Phase III Trials

A. Gottlieb, L. Uhlmann, G. Jemec, 2022, EMJ Dermatology.